In the first quarter of fiscal year ending March 2027, Kyorin Pharmaceutical reported net sales of approximately \u00a5296.5 billion, operating income of approximately \u00a596.4 billion, and net income of approximately \u00a582.4 billion, achieving increases compared to the same period last year.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4569-20260730-01.pdf","jir_short_summary":"In the first quarter of fiscal year ending March 2027, Kyorin Pharmaceutical reported net sales of approximately \u00a5296.5 billion, operating income of approximately \u00a596.4 billion, and net income of approximately \u00a582.4 billion, achieving increases compared to the same period last year.","jir_summary":"### Performance Overview\nIn the first quarter of fiscal year ending March 2027, Kyorin Pharmaceutical recorded net sales of \u00a529,654 million (YoY +1.9%), operating income of \u00a5964 million (YoY +59.3%), and net income of \u00a5824 million (YoY +60.8%), achieving growth in both sales and profit. Domestic and international pharmaceutical sales remained robust, with significant improvements driven by new drug launches and cost management efforts. Overseas business also performed well, with increased overseas sales.\n\n### Future Outlook and Impact on Investors\nThe company aims to continue expanding sales and profits through the launch of new drugs and promotion of existing products. Emphasis will be placed on overseas expansion and the introduction of new pharmaceuticals to drive long-term growth. For investors, improved profit margins and a stable growth outlook make the company an attractive investment, with expectations for share price appreciation.","jir_financial_highlights":"Net Sales: \u00a529,654 million (YoY +1.9\uff05)\nOperating Income: \u00a5964 million (YoY +59.3\uff05)\nNet Income: \u00a5824 million (YoY +60.8\uff05)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #EarningsReport, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a529,654 million (YoY +1.9\uff05)\nOperating Income: \u00a5964 million (YoY +59.3\uff05)\nNet Income: \u00a5824 million (YoY +60.8\uff05)","jir_meta_title":"\u3010Kyorin Pharmaceutical\u3011Q1 Fiscal Year Ending March 2027 Earnings\uff5cStrong Results with Revenue and Profit Growth","jir_meta_description":"Kyorin Pharmaceutical's Q1 earnings for fiscal year ending March 2027 reached net sales of \u00a5296.5 billion, operating income of \u00a596.4 billion, and net income of \u00a582.4 billion. Growth prospects are promising.","jir_og_title":"Kyorin Pharmaceutical Q1 FY2027 Earnings\uff5cStrong Revenue and Profit Growth","jir_og_description":"Kyorin Pharmaceutical's Q1 earnings for fiscal year ending March 2027 report net sales of approximately \u00a529,650 million, operating income of \u00a5964 million, and net income of \u00a5824 million. Future outlook is encouraging.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2026\\\",\\\"Q2 FY2026\\\",\\\"Q3 FY2026\\\",\\\"Q4 FY2026\\\",\\\"Q1 FY2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[29450,29500,29600,29700,29654],\\\"borderColor\\\":\\\"#36A2EB\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2026\\\",\\\"Q2 FY2026\\\",\\\"Q3 FY2026\\\",\\\"Q4 FY2026\\\",\\\"Q1 FY2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[900,920,940,960,964],\\\"borderColor\\\":\\\"#FF6384\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"net_income_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 FY2026\\\",\\\"Q2 FY2026\\\",\\\"Q3 FY2026\\\",\\\"Q4 FY2026\\\",\\\"Q1 FY2027\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[810,820,830,820,824],\\\"borderColor\\\":\\\"#4BC0C0\\\",\\\"fill\\\":false}]}}\"}, {\"jir_chart_id\": \"profit_margin\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Profit Margin Composition\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"pie\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Operating Profit Margin\\\",\\\"Net Profit Margin\\\"],\\\"datasets\\\":[{\\\"data\\\":[3.3,2.8],\\\"backgroundColor\\\":[\\\"#FF6384\\\",\\\"#36A2EB\\\"]}]}}\"}]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-90548","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n